Interventions to reduce haemorrhage during myomectomy for fibroids.

Kongnyuy EJ, Wiysonge CS

The Cochrane database of systematic reviews9 Nov 2011Cited by 9 (Europe PMC)

PMID22071823DOI10.1002/14651858.cd005355.pub4PepBankPUB-22071823

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

01HumanSystematic reviewEfficacy outcome
In women having myomectomy, intravenous oxytocin showed no evidence of an effect on blood loss in a Cochrane review of randomised trials.
In plain wordsIn women having fibroid surgery, intravenous oxytocin did not clearly reduce blood loss in a review of trials.
Peptide
Oxytocin
Outcome
No significant changeBlood loss during myomectomy
Study
n: not reported in source
Comparator
Placebo or no treatment
Outcome group
Bleeding and clotting · Reproductive and sexual health
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
There was no evidence of an effect on blood loss with oxytocin or morcellation.
2 context sentences(design, population, supporting numbers)
Summary · context
Only randomised controlled trials (RCTs) that compared the use of interventions to reduce blood loss during myomectomy to placebo or no treatment were included.
Summary · context
The interventions were intramyometrial vasopressin (two RCTs), intravenous oxytocin (two RCTs), peri-cervical tourniquet (two RCTs), and one RCT each for vaginal misoprostol, gelatin thrombin matrix, chemical dissection with sodium-2-mercaptoethane sulfonate (mesna), intramyometrial bupivacaine plus…
Report a problemFND-2207182301

Studies that did not test the peptide alone1

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

02HumanNot a test of Oxytocin aloneSystematic reviewSafety outcome
In women having myomectomy, none of the reviewed interventions, pooled, significantly increased myomectomy-related complications.
In plain wordsIn women having fibroid surgery, none of the reviewed treatments, taken together, clearly increased complications.
Peptide
Oxytocin
Outcome
No significant changeMyomectomy-related complications (all interventions)
Study
n: not reported in source
Comparator
Placebo or no treatment
Outcome group
Adverse events · Reproductive and sexual health
Source sentences
Summary
None of the interventions significantly increased myomectomy-related complications.
2 context sentences(design, population, supporting numbers)
Summary · context
Only randomised controlled trials (RCTs) that compared the use of interventions to reduce blood loss during myomectomy to placebo or no treatment were included.
Summary · context
The interventions were intramyometrial vasopressin (two RCTs), intravenous oxytocin (two RCTs), peri-cervical tourniquet (two RCTs), and one RCT each for vaginal misoprostol, gelatin thrombin matrix, chemical dissection with sodium-2-mercaptoethane sulfonate (mesna), intramyometrial bupivacaine plus…
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-2207182302

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 01:30 UTC
Study results updated
Version 1
9 Oct 2026, 02:51 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.